Dong Jin Park

Dr. Dong Jin Park

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
Dong Jin KimDong Jin Kim
Dong Jin Kim
JSJeong Ho Song
Jeong Ho Song
JPJi-Hyeon Park
Ji-Hyeon Park
SKSojung Kim
Sojung Kim
SPSin Hye Park
Sin Hye Park
TAThe Information Committee of the Korean Gastric Cancer Association
The Information Committee of the Korean Gastric Cancer Association
Kim DJ, et al. J Gastric Cancer. 2024 Dec;25:e8. https://doi.org/10.5230/jgc.2025.25.e8

1 December 2005 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
HKHawk Kim
Hawk Kim
JPJae-Hoo Park
Jae-Hoo Park
SBSung-Jo Bang
Sung-Jo Bang
DKDo-Ha Kim
Do-Ha Kim
HCHong Rae Cho
Hong Rae Cho
YMYoung Joo Min
Young Joo Min
Background: Docetaxel plus cisplatin (DP) is a combination chemotherapy regimen that is active against untreated advanced gastric cancer. We evaluated the feasibility of DP treatment in patients with recurring or metastatic gastric cancer who had been previously treated with other chemotherapy regimens. Patients and methods: The DP regimen consisted of doxetaxel (75 mg/m2 i.v.). and cisplatin (60 mg/m2 i.v.) over 1 h on Day 1 every 4 weeks for a maximum of nine cycles. Results: Thirty-seven patients (28 men, 9 women; median age, 53 years; range 28–71 years) received a total of 128 cycles of therapy (median, 3; range 1–9). Twenty-six patients had recurrent disease and 11 had metastatic tumors. The objective response rate was 32.4% (95% confidence interval = 16.6–48.3%), including 1 complete response and 11 partial responses. Eleven had stable disease, whereas 12 had progressive disease. The median duration of response was 70.5 days (range 30–392 days). Grade 3/4 toxicities included anemia (10.8%), leukopenia (27.0%), neutropenia (51.4%), thrombocytopenia (2.7%), nausea/vomiting (5.4%) and oral mucositis (13.5%). Median time to progression was 136 days and median overall survival was 235 days. Conclusion: The DP combination was well tolerated and effective for patients with metastatic gastric cancer treated previously with 5-fluorouracil/platinum chemotherapy.

1 March 2018 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
DPDong Jin Park
Dong Jin Park
BKByung Gyu Kim
Byung Gyu Kim
IJIn Du Jeong
In Du Jeong
GKGyu Yeol Kim
Gyu Yeol Kim
A 58-year-old man underwent laparoscopy-assisted distal gastrectomy (LADG) with Billroth I gastroduodenostomy due to early gastric cancer. During surgery, the perigastric vessels were ligated with Hem-o-Lok clips. Esophagogastroduodenoscopy (EGD) 6 months later showed a fungating mass at the anastomosis site. Repeat EGD 1 year after LADG showed a Hem-o-Lok clip at the fungating mass lesion. Because the patient was asymptomatic, with no major abnormalities on clinical examination, and endoscopic removal of the clip would have been difficult due to the presence of adhesions and inflammation, no attempt was made to remove the clip. The patient remained well after the exposed Hemo-Lok clip was identified. A third EGD 6 months later showed that the clip had disappeared from the anastomosis site, and that this site was covered with normal mucosa surrounding the scar.


1 January 2019 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
JKJin Sung Kim
Jin Sung Kim
EPEun Young Park
Eun Young Park
DPDong Jin Park
Dong Jin Park
GKGyu Yeol Kim
Gyu Yeol Kim
Kim JS, et al. J Gastric Cancer. 2019 Apr;19:e30. https://doi.org/10.5230/jgc.2019.19.e30

1 January 2025 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
HKHyoungil Kim
Hyoungil Kim
HSHo Seok Seo
Ho Seok Seo
HHHoon Hur
Hoon Hur
CLChang Min Lee
Chang Min Lee
SASang-Hoon Ahn
Sang-Hoon Ahn
HLHan Hong Lee
Han Hong Lee
Kim HI, et al. J Gastric Cancer. 2025 Jul;25(3):437-454. https://doi.org/10.5230/jgc.2025.25.e34